Biotech entity
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention 4D Medical, the most common co-covered peer. The 29-day window averages about 0.5 stories each week. The 6 average consequence score is below the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. Of the tracked stories, 1 of 2 also mention 4D Medical, the most common co-covered peer. The 29-day window averages about 0.5 stories each week. The 6 average consequence score is below the beat benchmark of 6.1 in the same window. Each story carries 3.5 original sources on average, compared with 3.4 for the broader beat in this window. This profile follows 2 Biotech stories mentioning Clarity Pharmaceuticals across the period from February 25, 2026 to March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 386 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Clarity Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials.
The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
Clarity Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
